Research Library

open-access-imgOpen AccessRisk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III
Lee YongWha,
Min WonKi,
Lee Woochang,
Chun Sail,
Park Hyosoon,
Lee DoHoon,
Lee You Kyoung
Publication year2007
Publication title
journal of clinical laboratory analysis
Resource typeJournals
PublisherWiley Subscription Services
Abstract The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), updated in 2001, quantified the risk factors and made it possible to assess risks for metabolic syndrome (MS) and coronary heart diseases (CHD). Many reported the prevalence of MS by NCEP ATP III in Orientals but few did risk analysis of CHD. We investigated the risk of CHD in Korean adults and the distribution of population for therapeutic lifestyle change (TLC) and drug therapy according to the NCEP ATP III guidelines. Based on ATP III risk factors, estimates of the 10‐year risk for CHD on 16,383 Koreans and the distributions of population for the TLC and additional drug therapy by sex and age were calculated. High‐, intermediate‐, and low‐risk groups were 8.1%, 24.1%, and 67.8%, respectively; 12.1% (high‐, intermediate‐, and low‐risk groups: 32.0%, 45.1%, and 6.0%, respectively) needed TLC and 6.1% (high‐, intermediate‐, and low‐risk groups: 39.4%, 16.6%, and 1.3%, respectively) needed additional drug therapy. The groups with higher risk needed more TLC and drug therapy. In the same age group, the rates of high risk in men showed a 1.0–6.6 fold increase compared with those in women. In Koreans, those who needed TLC and drug therapy were substantially lower than those in Americans. J. Clin. Lab. Anal. 21:178–182, 2007. © 2007 Wiley‐Liss, Inc.
Subject(s)cholesterol , disease , drug , environmental health , framingham risk score , medicine , metabolic syndrome , national cholesterol education program , obesity , pharmacology , pharmacotherapy , population
SCImago Journal Rank0.536

Seeing content that should not be on Zendy? Contact us.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here